1332392-76-3

Usage

Uses

Used in Pharmaceutical Industry:
5-bromo-2-chloro-3-(difluoromethyl)pyridine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique functional groups allow for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
5-bromo-2-chloro-3-(difluoromethyl)pyridine also serves as an intermediate in the production of agrochemicals, contributing to the creation of effective pesticides and other agricultural products to enhance crop protection and yield.
Used in Research and Development:
5-bromo-2-chloro-3-(difluoromethyl)pyridine is utilized as a building block in the synthesis of novel organic molecules for research purposes. Its properties and reactivity make it a valuable component in exploring new chemical reactions and developing innovative materials.
Used in Medicinal Chemistry:
5-bromo-2-chloro-3-(difluoromethyl)pyridine holds potential applications in medicinal chemistry, where its structural features can be leveraged to design and optimize new therapeutic agents targeting specific diseases or conditions.
Used in Materials Science:
5-bromo-2-chloro-3-(difluoromethyl)pyridine's synthesis and properties are of interest to researchers in materials science, where it may contribute to the development of advanced materials with unique properties for various applications.

Upstream product

• 228251-24-9 5-bromo-2-chloropyridine-3-carbaldehyde 
• 742100-75-0 (5-bromo-2-chloro-pyridin-3-yl)-methanol 
• 78686-79-0 methyl 2-chloro-5-bromonicotinate 

Relevant academic research and scientific papers

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

PLASMA KALLIKREIN INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS

Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disc

NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS

The present invention describes new pyrazolo-pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein, R1 is halogen, cyano, or C1-C3alkyl optionally substituted by halogen; R2 is C1-C6alkyl optionally substituted one or more times by C1-C6alkyl, C2-C6alkenyl, hydroxyl, N,N-di-C1-C6alkyl amino, N-mono-C1-C6alkyl amino, O-Rg, Rg, phenyl, or by C1-C6alkoxy wherein said alkoxy again may optionally be substituted by C1-C6alkoxy, N,N-di-C1-C6alkyl amino, Rg or phenyl; C3-C6cycloalkyl optionally substituted by C1-C6alkyl, N,N-di-C1-C6alkyl amino or C1-C6alkoxy-C1-C6alkyl, and/or two of said optional substituents together with the atoms to which they are bound may form an annulated or spirocyclic 4 - 6 membered saturated heterocyclic ring comprising 1 - 2 O atoms; phenyl optionally substituted by C1-C6alkoxy; a 5 - 6 membered heteroaryl ring having 1 to 3 heteroatoms selected from N and O said ring being optionally substituted by C1-C6alkyl which may be optionally substituted by amino or hydroxy; Rg; or N,N-di-C1-C6alkyl amino carbonyl; and R is phenyl independently substituted two or more times by Ra, 2-pyridyl independently substituted one or more times by Rb, 3-pyridyl independently substituted one or more times by Rc, or 4-pyridyl independently substituted one or more times by Rd; which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.